



Published in final edited form as:

Heart Rhythm. 2018 April ; 15(4): 607–614. doi:10.1016/j.hrthm.2017.11.018.

Ca²⁺ leak, what is it? Why should we care? Can it be managed?

Penelope A Boyden and

Department of Pharmacology, Center for Molecular Therapeutics, Columbia University, New York NY

Godfrey L. Smith

Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow UK

Abstract

For arrhythmia triggers that are secondary to dysfunctional intracellular Ca²⁺ cycling, there are few if any specific agents that target exactly the Ca²⁺ handling machinery. However, in the literature to date, several candidates have been proposed. We review here these agents with the idea that in the future these agents or those derived thereof will prove invaluable in clinical application.

INTRODUCTION

Under normal conditions for all cardiac cells, during systole, Ca²⁺ influx through the cardiac calcium channel provides a trigger for the calcium to be released from the sarcoplasmic reticulum (SR) through a large SR membrane, ligand operated, ion channel called the ryanodine receptor (RyR). The open probability of the RyR protein is increased by the elevation of cytoplasmic Ca²⁺ concentration [Ca²⁺]_i. Thus, Ca²⁺ entry into the cell produces a small increase of Ca²⁺ which leads to an opening of the RyR and subsequent release of a larger amount of Ca²⁺ that is stored in the SR. This process is known as calcium induced calcium release (CICR) (Figure 1). Microscopic signals resulting from clusters of RyR openings generate Ca²⁺ signals called Ca²⁺ sparks. Spatial and temporal summation of action potential evoked Ca²⁺ sparks underlies the global Ca²⁺ transient which in contractile cells has a familiar rise and decay as Ca²⁺ is released is reuptaken into the SR ready for the next heartbeat. Any remaining cytosolic Ca²⁺ is pumped out of cell by sodium calcium exchanger protein (NCX). Under normal conditions, CICR that occurs does not propagate but rather remains controlled by L type Ca²⁺ channel influx.

Address for Correspondence: Dr. Penelope A. Boyden, Dept of Pharmacology, Columbia College of Physicians and Surgeons, 630 West 168th ST. New York New York 10032, 212-305-7907 (phone), pab4@columbia.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

PAB: no conflicts

GS Smith has interests in Clyde Biosciences LTD UK, non-salaried

GLS: consult CLYDE BIOSciences

So what is “Ca²⁺ leak” if the cell always has spontaneous Ca²⁺ sparks, albeit at low probability?

When a cell is “overloaded” with calcium the associated sequestration of Ca²⁺ by the SR can increase SR Ca²⁺ content to above normal levels, under these circumstances the Ca²⁺ leaks out of the SR in the form of Ca²⁺ waves. These are local Ca²⁺ release events that trigger a regenerative Ca²⁺ waves via the CICR process. The Ca²⁺ wave can propagate throughout the cell and in some cases can trigger a Ca²⁺ waves in an adjacent cell (Figure 2)(see also¹). It appears that intracellular Ca²⁺ waves generally occur when the SR Ca²⁺ content is elevated above a threshold value^{2, 3}, but other changes, such as altered Ca²⁺ sensitivity of the RyR can induced Ca²⁺ waves. Some of the Ca²⁺ in the wave is pumped out of the cell by the electrogenic NCX. The resulting current depolarizes the membrane (producing a delayed afterdepolarization (DAD) like membrane voltage change) and can be sufficient to initiate an action potential. Yet synchrony of Ca²⁺ releases between coupled cells is required for to provide sufficient depolarizing current within one region to initiate an arrhythmic action potential in an intact ventricle/atrium. The critical number of coupled cells experiencing a DAD is a topic of debate and research⁴⁻⁶.

SR Ca²⁺ leak is increased in numerous pathological conditions (eg. Heart failure (HF)⁷; post MI^{8, 9}). SR Ca²⁺ leak, if persistent, decreases SR Ca²⁺ load and as explained above can lead to propagating Ca²⁺ waves and thus DADs (Figure 3).

While Ca²⁺ leak is an operational term, several mechanisms have been proposed to explain the altered RYR gating that leads to Ca²⁺ leak. An increased sensitivity of RYR to its ligand cytosolic Ca²⁺ may be due to enhanced protein kinase A (PKA) and/or CaMKII dependent RYR⁷ phosphorylation at specific sites^{10, 11-13}. Recent data using human tissues favor one idea where Ca²⁺ handling abnormalities in HF are due to excessive CaMKII phosphorylation at a specific RYR residue^{14, 15}. Other factors such as the oxidative state could change resulting in direct activation of the RYR protein¹⁶. Finally others have suggested that RYR gating may be altered when an abundance of endogenous proteins that modulate RYR are altered (eg. sorcin, S100A^{17, 18}).

Finally mutations and dysregulation of RYR and other calcium binding proteins have been implicated in several gene-based arrhythmias; for example, RYR and CVPT, and Calsequestrin(CASQ) and CPVT¹⁹. Mechanisms of these arrhythmias are similar to those of acquired diseases above, that is the arrhythmic events are caused by abnormally propagating Ca²⁺ waves which cause NCX dependent membrane oscillations (DADs) and triggered beats (Figures 2,3).

Can Ca²⁺ leak be Managed?

As an antiarrhythmic, we would want an agent to modulate the mishandled Ca²⁺ so Ca²⁺ does not increase Ca²⁺ dependent currents to cause depolarization and elicit action potentials. If we target the spontaneous Ca²⁺ releases, then we would reduce the initiators of the Ca²⁺ waves, the delayed afterdepolarizations and thus triggering beats.

The arrhythmias mentioned above result when the cell’s SR Ca²⁺ content is increased above a threshold level at which waves are produced. Recent work suggests that a decrease of

threshold (due to a sensitization to RYR Ca^{2+} release) also produces Ca^{2+} waves and DADs. For arrhythmias seen in heart failure the involvement of DADs in some ventricular arrhythmias has been shown^{20, 21}. However, in heart failure the SR Ca^{2+} content is decreased suggesting that the threshold for Ca^{2+} release may be lower, such that Ca^{2+} waves would occur at a lower SR Ca^{2+} content. This may be a consequence of increased leakiness of the RYR during diastole, such that there is increased Ca^{2+} efflux at a given SR Ca^{2+} content. The exact molecular mechanisms responsible for this are controversial²², but as above, it may be associated with increased phosphorylation of the RYR due to PKA or CaM-Kinase¹⁴.

An example of the occurrence of DADs in the absence of increased SR Ca^{2+} content is provided by catecholaminergic polymorphic ventricular tachycardia (CPVT). This arrhythmia in patients is seen during exercise or other stress. The similarity of the abnormalities in the ECGs to those observed in digitalis toxicity led to the suggestion of similarities in an underlying mechanism. Genetic studies have shown that many CPVT patients have a mutation in RYR (eg R4496C) or the intrasarcoplasmic protein CASQ (eg. R33Q). The current hypothesis is that the mutated protein causes an increased leak of Ca^{2+} from the SR. Thus Ca^{2+} waves and DADs occur at a lower SR Ca^{2+} content than in controls²³. (Figure 3)

Therapies for DAD-related arrhythmias

For these Ca^{2+} dependent (Ca^{2+} wave dependent) arrhythmias, the goal of therapy is to treat 1) to prevent the DAD from occurring and/or 2) to prevent the DAD from triggering an action potential.

The latter can potentially be achieved using sodium channel blockers. A better solution, however, would be to remove the underlying DAD directly. In the case of arrhythmias resulting from “calcium overload”, it may be possible to remove the underlying “overload”. For example, local anesthetics (eg. flecainide) reduce intracellular Na^+ concentration as a consequence of decreasing Na^+ entry (via inhibition of sodium current resulting in reduced excitability). Lowered intracellular Na^+ concentration will act via NCX, to decrease intracellular Ca^{2+} load²⁴. Antiarrhythmic effects of flecainide have been seen in murine models as well as patients with CPVT²⁵, but the confirmation that the cellular basis is linked to intracellular Na^+ levels has yet to be made.

Recently, the late Na^+ current ($I_{\text{Na-late}}$) has gained interest since it is modulated in disease. A small fraction of cardiac sodium channels carry $I_{\text{Na-late}}$. For peak I_{Na} , sodium channels open quickly and close in a well-defined time and voltage dependent manner. $I_{\text{Na-late}}$ current is formed when sodium channels remain open or reopen for 100s of ms after the peak current.

In HF and congenital long QT type3, $I_{\text{Na-late}}$ is upregulated and provides enhanced Na^+ influx during the AP²⁶. This in turn alters Ca^{2+}_i which then could be arrhythmogenic²⁷.

Ranolazine inhibits cardiac $I_{\text{Na-late}}$ as well as other channels (eg I_{Kr})²⁸. Some have reported it also inhibits RyR directly²⁹. It has been reported to have antiarrhythmic properties in various animal models (eg HF,^{30, 31}). In recent clinical trials it was demonstrated to reduce

arrhythmic events^{32, 33} although there appears to be a risk of Torsades de Pointes³⁴. GS-967 is a newer more specific $I_{Na-late}$ current inhibitor (lacks the I_{Kr} blockade seen with Ranolazine) that shows promise as an antiarrhythmic^{35, 36}.

While Na^+ channel blockade of the cardiac Na^+ channel is considered now to be a viable therapy for Ca^{2+} mediated arrhythmias, new data suggest that selective blockade of Neuronal Na^+ channels (eg. Nav1.1, Nav1.3 and Nav1.6s etc) in cardiac T-tubules using riluzole is anti-arrhythmic³⁷. This suggests that there is a contribution of Na^+ influx from overactive neuronal Na^+ channels in RYR subcellular regions to more Ca^{2+} leak from SR (Figure 4).

Theoretically, it would be possible to modulate Ca^{2+} by affecting the membrane transports/channels involved in Ca^{2+} homeostasis. For example, L type Ca^{2+} channel pore blockers obviously decrease Ca^{2+} influx and in so doing would be expected to eventually reduce SR load, Ca^{2+}_i and diminish force. Thus Ca^{2+} channel pore blockers (eg. Verapamil) will affect intracellular Ca^{2+} and wave formation but at the expense of force generation. An alternative option to drugs acting directly on molecular targets of the SR is to modulate sarcolemma Ca^{2+} influxes that in turn reduce SR Ca^{2+} load and therefore associated Ca^{2+} -leak related abnormalities. As with other targets, the risk associated with reduced SR Ca^{2+} load is that peak systolic Ca^{2+} will be reduced and associated inotropy. Currently accepted medications such as Ca^{2+} channel blockers and beta blockers reduce cardiovascular mortality partially via reduction of Ca^+ influx to the heart through their effects on the L-type Ca^{2+} channel. But the relative contribution of SR unloading to the overall beneficial effect of these two classes of drugs is difficult to assess.

Alternatively, one might target the molecular mechanism involved in the inactivation of Ca^{2+} channel proteins or the Ca^{2+} dependent processes known to affect Ca^{2+} channel function (eg. CaMKII) or small proteins (eg. Gem) that are known to affect Ca^{2+} channel subunit assembly³⁸.

Phosphorylation/dephosphorylation of the enzyme CaMKII is critical for cardiac excitability and function much like its well-known “neighborhood” protein, protein kinase A (PKA). Unlike PKA, CaMKII has the ability to become autophosphorylated and this is a Ca^{2+} independent process³⁹. But like PKA, CaMKII activity is linked to the function of several intracellular cardiac proteins, for example, the L type Ca^{2+} channel⁴⁰ and RYR⁴¹. Thus targeting inhibition of this enzyme to alter function of regulated proteins to ameliorate Ca^{2+} wave function and resulting DADs is a goal of both academia and industry⁴².

At this time, only three tools are available. KN-93 (and its inactive analog KN-62) are used frequently in experimental studies to illustrate the role of CaMKII in cardiac cell function. KN-93 does inhibit activation of CaMKII but not its autophosphorylation activity. But CaMKII inhibition prevents catecholamine induced VTs in CPVT mice⁴³ and recently has proven useful on atrial arrhythmias secondary to Ca^{2+} leak⁴⁴.

However, KN93 affects L type Ca^{2+} channel function⁴⁵ as well as some K^+ channel function⁴⁶. Experimentalists have also used autocalmitide-3 inhibitor (AC3-1) peptides that inhibit CaMKII selectively over PKA, PKC⁴⁷. AC3-1 is also a potent PKD inhibitor. These

peptides remain as tools. There has also been a recent emergence of pharmacologically active agents designed after small endogenous proteins that inhibit CamKII, such as CaMKIIN⁴⁸ and CaMKIINide⁴⁹. Work continues to delineate how these inhibitors affect cardiac function.

Direct modulation of SR leak via actions on RYR channel

Designing drugs to bind to RYR directly to reduce the Ca²⁺ sensitivity of the channel is thought to be a valid anti-arrhythmic strategy, but no compounds to date have been approved for clinical use purely on this mechanism. While many drugs designed for other purposes have been found to alter RYR Ca²⁺ sensitivity, these have been used as tools to investigate the effects of drug-induced modulation of RYR. The anesthetics such as tetracaine, which reduces surface membrane excitability via Na⁺ channel inhibition is also known to reduce the sensitivity of Ca²⁺ induced SR Ca²⁺ release via a direct action on RYR⁵⁰. Studies have shown tetracaine substantially reduces the frequency of both Ca²⁺ sparks and spontaneous Ca²⁺ waves⁵¹ but this effect is accompanied by an increased quantity of Ca²⁺ released from the SR at each spontaneous event (increased leak). Derivatives of tetracaine that block RyR appear to inhibit SR Ca²⁺ leak and prevent CPVT arrhythmias in mice⁵². Caffeine, a compound known to increase the Ca²⁺ sensitivity of RYR will increase the frequency of sparks and Ca²⁺ waves and each release event is smaller⁵³. Interestingly, while these two compounds dramatically affect spontaneous Ca²⁺ release in different ways, the effect on systolic Ca²⁺ release (in the steady-state condition) is undetectable due to an autoregulatory mechanism involving Ca²⁺ influx via the L-type and Ca⁺ extrusion mainly via NCX²⁷. Caffeine is known to increase ventricular premature beats in normal hearts via its ability to increase the incidence of spontaneous Ca²⁺ waves and thus generate a spontaneous diastolic depolarization which generates triggers the extra systole. Many aspects of this explanation still require clarification.

Drugs have been identified that have an almost exclusive effect on the RYR protein complex to reduce Ca²⁺ sensitivity.

The first drug candidate to emerge was the benzodiazepine derivative variously known as JTV519/K201. This molecule is similar in structure to L-type Ca²⁺ channel blockers, but was selected for its ability to reduce the effects of intracellular Ca²⁺ overload⁵⁴. Subsequent work suggested that the drug's mechanism was to bind to RYR and mimic the binding of the regulatory protein FK506 binding protein (FKBP12.6)⁵⁵. FKBP12.6 is thought to bind to RYR and chronically reduce Ca²⁺ efflux through RYR. As part of the beta-adrenergic response, A-kinase mediated phosphorylation may alter the Ca²⁺ sensitivity of RYR via reduced binding of FKBP12.6. In HF, the associated altered status of the adrenergic signaling pathway in cardiac muscle is thought to result in hyper phosphorylation of RYR, reduced FKBP12.6 binding and thereby increase RYR-mediated Ca²⁺ leak from the SR, i.e. acting in an analogous way to caffeine⁵⁶. These changes are thought to be responsible for the failing myocardium being more prone to DADs and subsequent pro-arrhythmic VPCs. In support of this, JTV519 improved outcome in an animal model of HF⁵⁷. JTV519/K201 reduces Ca⁺ efflux via RYR at concentrations that allow reasonable specificity to RYR and appears to have an action in the absence of activation of the A-kinase pathway⁵⁸. Therefore,

regardless of the mechanism, the drug has the possibility to act via RYR as an antiarrhythmic agent on myocardium prone to arrhythmias due to dysfunctional RYR, e.g. Purkinje cells that survive in the infarcted heart⁸ (Figure 5). An alternative structure thought to be an even more potent inhibitor of RYR is variously known as S107 or RyCal^{10, 59, 60}. Others are currently being sought.

Dantrolene and dantrolene-like compounds while showing no effect on normal RyR function, inhibits Ca²⁺ leak in cells from failing hearts by promoting a stable RyR conformational state^{61–63}.

Action on other targets that may aid anti-arrhythmic effects

One feature of small molecules is a lack of specificity that may benefit or counteract their ability to suppress spontaneous Ca²⁺ release. For example, JTV519/K201 was found to inhibit SERCA activity by a small amount (~10%) at drug levels that also significantly suppress RYR activity⁵⁸. Suppression of SERCA is normally associated with smaller systolic Ca²⁺ releases and poor contractility in failing myocardium. Thus low levels of inhibition may not have the significant negative inotropic effects but could significantly suppress spontaneous Ca²⁺ waves and therefore arrhythmias. Data from several groups^{64–66} suggest that a burst of Ca²⁺-activated SERCA activity in regions of a cell adjacent to a region of spontaneous Ca²⁺ release could locally enhance SR load and increase the chance of spontaneous Ca²⁺ release propagating along the length of the cells. Thus mild SERCA inhibition may aid an anti-arrhythmic action through this route.

Studies on a CPVT mouse model and a limited number of human CPVT patients have shown that Flecainide (a Na⁺ channel blocker) can suppress arrhythmias associated with RYR dysfunction^{67, 68}. The study suggests that the mode of anti-arrhythmic action is not via Na⁺ channel inhibition, but via an inhibitory effect of flecainide on RYR⁶⁹. But this interpretation of flecainide's action on RYR has been challenged by isolated RYR studies⁷⁰ and in intact cell work⁷¹. Another example of a potential revision of the mode of action of a cardiovascular drug is the beta blocker Carvedilol. This drug is a potent inhibitor of RYR and may act to suppress arrhythmias through this route⁷². Further screens of beta-blockers have identified other examples of drugs that suppress RYR activity and therefore potentially possess anti-DAD and antiarrhythmic activity⁷³. Such examples indicate the challenges in designing anti-arrhythmic therapy around a single target with a single molecule and in assigning mechanism to the observed anti-arrhythmic effect. However, in a recent publication, derivatives of tetracaine with high specificity to RyR were found to effectively suppress arrhythmias in a mouse model of CPVT⁵² and indicates that drug-based RyR inhibition can have powerful anti-arrhythmic effects.

Alternative anti-arrhythmic strategies

Alternative approaches being considered are for example, inhibition of the NCX. This may appear a good strategy since this exchanger provides the major Ca⁺ activated currents (I_{ti}) in DADs^{73, 74}. But tonic inhibition of this exchanger will reduce the Ca²⁺ efflux capacity of the myocardium, increase intracellular Ca²⁺ and SR load and potentially increase the probability of pro-arrhythmic Ca²⁺ release. A second approach that may indirectly be anti-arrhythmic is

to use novel drugs designed to stimulate the sarcolemmal Na⁺/K⁺ pump/antiporter (NKA)⁷⁵. These are designed to restore the intracellular Na⁺ concentration and in doing so, may reduce cellular Ca²⁺ load via NCX, SR load and associated pro-arrhythmic SR Ca²⁺-leak.

In summary, pharmacological strategies that specifically address abnormal SR Ca⁺ leak are at early stages of development but hold great promise as a means of providing novel anti-arrhythmic therapeutic options for a range of cardiac pathologies with associated high risk of sudden arrhythmic cardiac death.

Acknowledgments

PA Boyden supported by NIH HL114383.

References

1. Bers DM. Cardiac Sarcoplasmic Reticulum Calcium Leak: Basis and Roles in Cardiac Dysfunction. *Annu Rev of Physiol.* 2014; 76:107–27. [PubMed: 24245942]
2. Diaz ME, Trafford AW, O’Neil CL, Eisner DA. A measurable reduction of SR Ca content follows spontaneous Ca release in rat ventricular myocytes. *Pfluegers Arch.* 1997; 434:852–4. [PubMed: 9306022]
3. Chen-Izu Y, Ward CW, Stark W Jr, Banyasz T, Sumandea MP, Balke CW, Izu LT, Wehrens XH. Phosphorylation of RyR2 and shortening of RyR2 cluster spacing in spontaneously hypertensive rat with heart failure. *Am J Physiol Heart Circ Physiol.* 2007; 293:H2409–H2417. [PubMed: 17630346]
4. Houser SR. When does spontaneous sarcoplasmic reticulum CA(2+) release cause a triggered arrhythmia? Cellular versus tissue requirements. *Circ Res.* 2000; 87(9):725–7. [PubMed: 11055973]
5. Xie Y, Sato D, Garfinkel A, Qu Z, Weiss JN. So little source, so much sink: requirements for afterdepolarizations to propagate in tissue. *Biophys J.* 2010; 99(5):1408–15. [PubMed: 20816052]
6. Myles RC, Wang L, Kang C, Bers DM, Ripplinger CM. Local beta-adrenergic stimulation overcomes source-sink mismatch to generate focal arrhythmia. *Circ Res.* 2012; 110(11):1454–64. [PubMed: 22539768]
7. Ai X, Curran JW, Shannon TR, Bers DM, Pogwizd SM. Ca²⁺/Calmodulin-Dependent Protein Kinase Modulates Cardiac Ryanodine Receptor Phosphorylation and Sarcoplasmic Reticulum Ca²⁺ Leak in Heart Failure. *Circ Res.* 2005; 97:1314–22. [PubMed: 16269653]
8. Hirose M, Stuyvers BD, Dun W, Ter Keurs HED, Boyden PA. Function of Ca²⁺ release channels in Purkinje cells that survive in the infarcted canine heart; a mechanism for triggered Purkinje ectopy. *Circ Arrhythmia Electrophys.* 2008; 1:387–95.
9. Belevych AE, Terentyev D, Terentyeva R, Ho HT, Gyorke I, Bonilla IM, Carnes CA, Billman GE, Györke S. Shortened Ca²⁺ Signaling Refractoriness Underlies Cellular Arrhythmogenesis in a Postinfarction Model of Sudden Cardiac Death. *Circ Res.* 2012; 110:569–77. [PubMed: 22223353]
10. Shan J, Betzenhauser MJ, Kushnir A, Reiken S, Li J, Lehnart SE, Lindegger N, Mongillo M, Mohler PJ, Marks AR. Role of chronic ryanodine receptor phosphorylation in heart failure and beta -adrenergic receptor blockade in mice. *J Clin Invest.* 2010; 120:4375–87. [PubMed: 21099115]
11. Belevych AE, Radwanäski PB, Carnes CA, Gyorke S. Ryanopathy: causes and manifestations of RyR2 dysfunction in heart failure. *CARDIOVASC RES.* 2013; 98:240–7. [PubMed: 23408344]
12. Curran J, Brown KH, Santiago DJ, Pogwizd S, Bers DM, Shannon TR. Spontaneous Ca waves in ventricular myocytes from failing hearts depend on Ca²⁺-calmodulin-dependent protein kinase II. *J Mol Cell Cardiol.* 2010; 49:25–32. [PubMed: 20353795]
13. Curran J, Hinton MJ, Rios E, Bers DM, Shannon TR. Beta -Adrenergic Enhancement of Sarcoplasmic Reticulum Calcium Leak in Cardiac Myocytes Is Mediated by Calcium/Calmodulin-Dependent Protein Kinase. *Circ Res.* 2007; 100:391–8. [PubMed: 17234966]

14. Respress JL, van Oort RJ, Li N, Rolim N, Dixit SS, deAlmeida A, Voigt N, Lawrence WS, Skapura DG, Skårdal K, Wisløff U, Wieland T, Ai X, Pogwizd SM, Dobrev D, Wehrens XH. Role of RyR2 Phosphorylation at S2814 During Heart Failure Progression. *Circ Res.* 2012 May 24;110:1474. [PubMed: 22511749]
15. Fischer TH, Herting J, Tirilomis T, Renner A, Neef S, Toischer K, Ellenberger D, Förster A, Schmitto JD, Gummert J, Schönöube FA, Hasenfuss G, Maier LS, Sossalla S. Ca²⁺/Calmodulin-Dependent Protein Kinase II and Protein Kinase A Differentially Regulate Sarcoplasmic Reticulum Ca²⁺ Leak in Human Cardiac Pathology. *Circ.* 2013; 128:970–81.
16. Terentyev D, Gyorke I, Belevych AE, Terentyeva R, Sridhar A, Nishijima Y, de Blanco EC, Khanna S, Sen CK, Cardounel AJ, Carnes CA, Györke S. Redox Modification of Ryanodine Receptors Contributes to Sarcoplasmic Reticulum Ca²⁺ Leak in Chronic Heart Failure. *Circ Res.* 2008; 103:1466–72. [PubMed: 19008475]
17. Farrell EF, Antaramian A, Rueda A, Gomez AM, Valdivia HcH. Sorcin Inhibits Calcium Release and Modulates Excitation-Contraction Coupling in the Heart. *J Biol Chem.* 2003; 278:34660–6. [PubMed: 12824171]
18. Most P, PLegeer ST, Volkens M, et al. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. *J Clin Invest.* 2004; 114:1550–63. [PubMed: 15578088]
19. Cerrone M, Cummings S, Alansari T, Priori SG. A Clinical Approach to Inherited Arrhythmias. *Circ: Cardiovasc Gene.* 2012; 5:581–90.
20. Pogwizd SM, McKenzie JP, Cain ME. Mechanisms Underlying Spontaneous and Induced Ventricular Arrhythmias in Patients With Idiopathic Dilated Cardiomyopathy. *Circ.* 1998; 98:2404–14.
21. Janse MJ. Electrophysiological changes in heart failure and their relationship to arrhythmogenesis. *CARDIOVASC RES.* 2004; 61:208–17. [PubMed: 14736537]
22. Bers DM, Eisner DA, Valdivia HH. Sarcoplasmic Reticulum Ca²⁺ and Heart Failure: Roles of Diastolic Leak and Ca²⁺ Transport. *Circ Res.* 2003; 93:487–90. [PubMed: 14500331]
23. Liu N, Colombi B, Memmi M, Zissimopoulos S, Rizzi N, Negri S, Imbriani M, Napolitano C, Lai FA, Priori SG. Arrhythmogenesis in Catecholaminergic Polymorphic Ventricular Tachycardia: Insights From a RyR2 R4496C Knock-In Mouse Model. *Circ Res.* 2006; 99:292–8. [PubMed: 16825580]
24. Sikkell MB, Collins TP, Rowlands C, Shah M, O’Gara P, Williams AJ, Harding SE, Lyon AR, MacLeod KT. Flecainide reduces Ca²⁺ spark and wave frequency via inhibition of the sarcolemmal sodium current. *CARDIOVASC RES.* 2013; 98:286–96. [PubMed: 23334259]
25. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AA, Knollmann BC. Flecaïnide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. *Nat Med.* 2009; 15:380–3. [PubMed: 19330009]
26. Bjornstad H, Tande PM, Lathrop DA, Refsum H. Effects of temperature on cycle length dependent changes and restitution of action potential duration in guinea pig ventricular muscle. *Cardiovasc Res.* 1993; 27(6):946–50. [PubMed: 8221783]
27. Eisner DA, Trafford AW, Diaz ME, Overend CL, O’Neill SC. The control of Ca²⁺ release from the cardiac sarcoplasmic reticulum: regulation versus autoregulation. *Cardiovasc Res.* 1998; 38(3): 589–604. [PubMed: 9747428]
28. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas G. Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties. *Circ.* 2004; 110:904–10.
29. Parikh A, Mantravadi R, Kozhevnikov D, Roche MA, Ye Y, Owen LJ, Puglisi JL, Abramson JJ, Salama G. Ranolazine stabilizes cardiac ryanodine receptors: A novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2. *Heart Rhythm.* 2012; 9:953–60. [PubMed: 22245792]
30. Burashnikov A, Di Diego JM, Barajas-Martinez H, Hu D, Cordeiro JM, Moise NS, Kornreich BG, Belardinelli L, Antzelevitch C. Ranolazine Effectively Suppresses Atrial Fibrillation in the Setting of Heart Failure. *Circ: Heart Failure.* 2014; 4:627–33.
31. Burashnikov A, Di Diego JM, Sicouri S, Doss MX, Sachinidis A, Barajas-Martínez H, Hu D, Minoura Y, Sydney Moise N, Kornreich BG, Chi L, Belardinelli L, Antzelevitch C. A temporal

- window of vulnerability for development of atrial fibrillation with advancing heart failure. *Eur J Heart Fail.* 2014; 16:271–80. [PubMed: 24464846]
32. Nieminen T, Scirica BM, Pegler JRM, Tavares C, Pagotto VP, Kanas AF, Sobrado MF3, Nearing BD, Umez-Eronini AA, Morrow DA, Belardinelli L, Verrier RL. Relation of T-Wave Alternans to Mortality and Nonsustained Ventricular Tachycardia in Patients With NonST-Segment Elevation Acute Coronary Syndrome from the MERLIN-TIMI 36 Trial of Ranolazine Versus Placebo. *Am J Cardiol.* 2014; 114:17–23. [PubMed: 24852915]
 33. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, Verheugt FW, Gersh BJ, McCabe CH, Braunwald E. Effect of Ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Non ST-Segment Elevation Acute Coronary Syndrome: Results From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial. *Circ.* 2007; 116:1647–52.
 34. Gong M, Zhang Z, Fragakis N, Korantzopoulos P, Letsas KP, Li G, Yan GX, Liu T. Role of ranolazine in the prevention and treatment of atrial fibrillation: A meta-analysis of randomized clinical trials. *Heart Rhythm.* 2017; 14(1):3–11. [PubMed: 27746384]
 35. Sicouri S, Belardinelli L, Antzelevitch C. Antiarrhythmic effects of the highly selective late sodium channel current blocker GS-458967. *Heart Rhythm.* 2013; 10:1036–43. [PubMed: 23524321]
 36. Belardinelli L, Liu G, Smith-Maxwell C, Wang WQ, El-Bizri N, Hirakawa R, Karpinski S, Li CH, Hu L, Li XJ, Crumb W, Wu L, Koltun D, Zablocki J, Yao L, Dhalla AK, Rajamani S, Shryock JC. A Novel, Potent, and Selective Inhibitor of Cardiac Late Sodium Current Suppresses Experimental Arrhythmias. *JPET.* 2013; 344:23–32.
 37. Veeraghavan R, Gyorke S, Radwanski PB. Neuronal sodium channels: emerging components of the nano-machinery of cardiac calcium cycling. *J Physiol.* 2017; 595:3823–3934. [PubMed: 28195313]
 38. Puckerin AA, Chang DD, Subramanyam P, Colecraft HM. Similar molecular determinants on Rem mediate two distinct modes of inhibition of CaV1. 2 channels *Channels.* 2016; 10:379–94. [PubMed: 27115600]
 39. Purohit A, Rokita AG, Guan X, Chen B, Koval OM, Voigt N, Neef S, Sowa T, Gao Z, Luczak ED, Stefansdottir H, Behunin AC, et al. Oxidized Ca²⁺/Calmodulin-Dependent Protein Kinase II Triggers Atrial Fibrillation. *Circ.* 2013; 128:1748–57.
 40. Grueter CE, Abiria SA, Wu Y, Anderson ME, Colbran RJ. Differential Regulated Interactions of Calcium/Calmodulin-Dependent Protein Kinase II with Isoforms of Voltage-Gated Calcium Channel Subunits. *Biochemistry.* 2008; 47:1760–7. [PubMed: 18205403]
 41. Wang, Li N., Wang, TW., et al. Inhibition of CaMKII Phosphorylation of RyR2 Prevents Induction of Atrial Fibrillation in FKBP12.6 Knockout Mice. *Circ Res.* 2012 Feb 3.110:465–70. [PubMed: 22158709]
 42. Pellicena P, Schulman H. CaMKII Inhibitors: From Research Tools to Therapeutic Agents. *Front Pharm.* 2014; 5
 43. Liu N, Ruan Y, Denegri M, Bachetti T, Li Y, Colombi B, Napolitano C, Coetzee WA, Priori SG. Calmodulin kinase II inhibition prevents arrhythmias in RyR2R4496C mice with catecholaminergic polymorphic ventricular tachycardia. *J Mol Cell Cardiol.* 2011; 50:214–22. [PubMed: 20937285]
 44. Chelu MG, Sarma S, Sood S, Wang S, van Oort RJ, Skapura DG, Li N, Santonastasi M, Müller FU, Schmitz W, Schotten U, Anderson ME, et al. CaMKII-mediated SR Ca leak promotes atrial fibrillation in mice. *J Clin Invest.* 2009; 119:1940–51. [PubMed: 19603549]
 45. Anderson ME, Braun AP, Wu YLT, Wu Y, Schulman H, Sung RJ. KN-93, an inhibitor of multifunctional Ca⁺⁺/Calmodulin-dependent protein kinase, Decreases early afterdepolarizations in rabbit heart. *JPET.* 1998; 287:996–1006.
 46. Rezazadeh S, Claydon TW, Fedida D. KN-93 (2-[N-(2-Hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), a Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor, Is a Direct Extracellular Blocker of Voltage-Gated Potassium Channels. *JPET.* 2006; 317:292–9.

47. Backs J, Backs T, Neef S, Kreusser MM, Lehmann LH, Patrick DM, Grueter CE, Qi X, Richardson JA, Hill JA, Katus HA, Bassel-Duby R, et al. The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. *PNAS*. 2009; 106:2342–7. [PubMed: 19179290]
48. Chang BH, Mukherji S, Soderling TR. Calcium/calmodulin-dependent protein kinase II inhibitor protein: localization of isoforms in rat brain. *Neuroscience*. 2001; 102:767–77. [PubMed: 11182241]
49. Vest RS, Davies KD, O’Leary H, Port JD, Bayer KU. Dual Mechanism of a Natural CaMKII Inhibitor. *Mol Biol Cell*. 2007; 18:5024–33. [PubMed: 17942605]
50. Zahradnikova A, Palade P. Procaine effects on single sarcoplasmic reticulum Ca²⁺ release channels. *Biophys J*. 1993; 64(4):991–1003. [PubMed: 8388270]
51. Overend CL, Eisner DA, O’Neill SC. The effect of tetracaine on spontaneous Ca²⁺ release and sarcoplasmic reticulum calcium content in rat ventricular myocytes. *J Physiol*. 1997; 502:471–9. [PubMed: 9279801]
52. Li N, Wang Q, Sibrian-Vazquez M, Klipp RC, Reynolds JO, Word TA1, Scott L Jr, Salama G, Strongin RM, Abramson JJ, Wehrens XHT. Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs. *Int J Cardiol*. 2017; 227:668–73. [PubMed: 27838126]
53. Venetucci LA, Trafford AW, Eisner DA. Increasing ryanodine receptor open probability alone does not produce arrhythmogenic calcium waves: threshold sarcoplasmic reticulum calcium content is required. *Circ Res*. 2007 Jan 5; 100(1):105–11. [PubMed: 17110597]
54. Hachida M, Kihara S, Nonoyama M, Koyanagi H. Protective effect of JTV519, a new 1,4-benzothiazepine derivative, on prolonged myocardial preservation. *J Card Surg*. 1999; 14(3):187–93. [PubMed: 10789707]
55. Wehrens XH, Lehnart SE, Reiken S, Deng SX, Vest JA, Cervantes D, Coromilas J, Landry DW, Marks AR. Protection from cardiac arrhythmia through ryanodine receptor stabilizing protein calstabin2. *Science*. 2004; 304:292–6. [PubMed: 15073377]
56. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosembli N, Marks AR. PKA Phosphorylation Dissociates FKBP12.6 from the Calcium Release Channel (Ryanodine Receptor): Defective Regulation in Failing Hearts. *Cell*. 2000; 101:365–76. [PubMed: 10830164]
57. Wehrens XH, Lehnart SE, Reiken S, van der Nagel R, Morales R, Sun J, Cheng Z, Deng SX, de Windt LJ, Landry DW, Marks AR. Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure. *Proc Natl Acad Sci USA*. 2005; 102(27):9607–12. [PubMed: 15972811]
58. Loughrey CM, Otani N, Seidler T, Craig MA, Matsuda R, Kaneko N, Smith GL. K201 modulates excitation-contraction coupling and spontaneous Ca²⁺ release in normal adult rabbit ventricular cardiomyocytes. *CARDIOVASC RES*. 2007; 76:236–46. [PubMed: 17644079]
59. Lehnart SE, Mongillo M, Bellinger A, Lindegger N, Chen BX, Hsueh W, Reiken S, Wronska A, Drew LJ, Ward CW, Lederer WJ, Kass RS, et al. Leaky Ca²⁺ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. *J Clin Invest*. 2008; 118(6):2230–45. [PubMed: 18483626]
60. Sasaki K, Makiyama T, Yoshida Y, Wuriyanghai Y, Kamakura T, Nishiuchi S, Hayano M, Harita T, Yamamoto Y, Kohjitani H, Hirose S, Chen J, et al. Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia. *PLoS ONE*. 2016; 11:e0164795. [PubMed: 27764147]
61. Maxwell JT, Domeier TL, Blatter LA. Dantrolene prevents arrhythmogenic Ca release in heart failure. *AmPhysiology - Heart Circ Physiol*. 2012; 302:H953.
62. Uchinoumi H, Yang Y, Oda T, Ca Li N, Alsina KM, Puglisi JL, Chen-Izu Y, Cornea RL, Wehrens XHT, Bers DM. MKII-dependent phosphorylation of RyR2 promotes targetable pathological RyR2 conformational shift. *J Mol Cell Cardiol*. 2016; 98:62–72. [PubMed: 27318036]
63. Hartmann N, Pabel S, Herting J, Schatter F, Gummert J, Schotola H, Danner BC, Maier LS, Frey N, Hasenfuss G, Fischer TH, Sossalla S. Antiarrhythmic effects of dantrolene in human diseased cardiomyocytes. *Heart Rhythm*. 2017; 14:412–9. [PubMed: 27650424]

64. Keller M, Kao JP, Egger M, Niggli E. Calcium waves driven by “sensitization” wave-fronts. *Cardiovasc Res.* 2007; 74(1):39–45. [PubMed: 17336953]
65. Smith GL, O’Neill SC. A comparison of the effects of ATP and tetracaine on spontaneous Ca^{2+} release from rat permeabilised cardiac myocytes. *J Physiol.* 2001;534: 37–47.
66. Luyananen V, Gyorke I, Gyorke S. Regulation of calcium release by calcium inside the sarcoplasmic reticulum in ventricular myocytes. *Pfluegers Arch.* 1996; 432:1047–54. [PubMed: 8781199]
67. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AA, Knollmann BC. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. *Nat Med.* 2009; 15(4):380. [PubMed: 19330009]
68. Kannankeril PJ, Moore JP, Cerrone M. Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: A randomized clinical trial. *JAMA Cardiology.* 2017; 2:759–66. [PubMed: 28492868]
69. Hilliard FA, Steele DS, Laver D, Yang Z, Le Marchand SJ, Chopra N, Piston DW, Huke S, Knollmann BC. Flecainide inhibits arrhythmogenic Ca^{2+} waves by open state block of ryanodine receptor Ca^{2+} release channels and reduction of Ca^{2+} spark mass. *J Mol Cell Cardiology.* 2010; 48:293–301.
70. Bannister ML, Thomas NL, Sikkil MB, Mukherjee S, Maxwell C, MacLeod KT, George CH, Williams AJ. The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2. *Circ Res.* 2015; 116(8):1324–35. [PubMed: 25648700]
71. Sikkil MB, Collins TP, Rowlands C, Shah M, O’Gara P, Williams AJ, Harding SE, Lyon AR, MacLeod KT. Triple mode of action of flecainide in catecholaminergic polymorphic ventricular tachycardia: reply. *Cardiovasc Res.* 2013; 98(2):327–8. [PubMed: 23536607]
72. Zhou Q, Xiao J, Jiang D, Wang R, Vembaiyan K, Wang A, Smith CD, Xie C, Chen W, Zhang J, Tian X, Jones PP, et al. Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca^{2+} release. *Nat Med.* 2011; 17(8):1003–9. [PubMed: 21743453]
73. Tan Z, Xiao Z, Wei J, Zhang J, Zhou Q, Smith CD, Nani A, Wu G, Song LS, Back TG, Fill M, Chen SR. Nebivolol suppresses cardiac ryanodine receptor-mediated spontaneous Ca^{2+} release and catecholaminergic polymorphic ventricular tachycardia. *Biochem J.* 2016; 473(22):4159–72. [PubMed: 27623776]
74. Kohajda Z, Farkas-Morvay N, Jost N, Nagy N, Geramipour A, Horváth A, Varga RS, Hornyik T, Corici C, Acsai K, Horváth B, Prorok J, et al. The Effect of a Novel Highly Selective Inhibitor of the Sodium/Calcium Exchanger (NCX) on Cardiac Arrhythmias in In Vitro and In Vivo Experiments. *PLoS ONE.* 2016; 11(11):e0166041. [PubMed: 27832106]
75. Fuller W, Tulloch LB, Shattock MJ, Calaghan SC, Howie J, Wypijewski KJ. Regulation of the cardiac sodium pump. *Cell Mol Life Sci.* 2013; 70(8):1357–80. [PubMed: 22955490]
76. Ter Keurs HEDJ, Boyden PA. Calcium and Arrhythmogenesis. *Physiol Rev.* 2007; 87:457–506. [PubMed: 17429038]
77. Liu N, Denegri M, Dun W, et al. Abnormal propagation of calcium waves and ultrastructural remodeling in recessive catecholaminergic polymorphic ventricular tachycardia. *Circ Res.* 2013; 113(2):142–52. [PubMed: 23674379]




Figure 1. Simple diagram of the excitation-contraction coupling system in the cardiac cell
 During the action potential Ca^{2+} enters the cell as a rapid influx followed by a maintained component of the slow inward Ca^{2+} current (Thick arrow). The rapid influx of Ca^{2+} via the T tubules is thought to induce release of Ca^{2+} from a release compartment in the SR, by triggering opening of Ca^{2+} channels via binding sites(sensors) on RYR protein. Relaxation follows when the cytosolic Ca^{2+} is sequestered again in an uptake compartment of the SR (SERCA pump, green boxes) and partly extruded through the cell membrane by the $\text{Na}^+/\text{Ca}^{++}$ exchanger (NCX). The process of NCX is electrogenic so that Ca^{2+} extrusion through NCX leads to a depolarizing current. From Ter Keurs and Boyden, *Physiol Review*, 2007⁷⁶.




Figure 2. Representative confocal line-scan images show spontaneous Ca²⁺ release events (SCaEs) in wild-type (WT) and R33Q (CPVT mutation in CASQ) cells in the presence of isoproterenol

Black arrows indicate field stimulations. Spontaneous Ca events (SCaEs) in WT myocytes were usually due to a cell-wide wave that was initiated at 1 site (red arrow). SCaEs in diseased R33Q cells varied. Often, fragmented spontaneous Ca²⁺ waves occurred and slowly propagated (cells 1 and 2), and wavelets and Ca²⁺ sparks occurred before Ca²⁺ transients resume the diastolic level. From Liu N et al. *Circulation Research* 2013;113:142–152⁷⁷.




Figure 3. Action potentials recordings in a R33Q mouse cells in the presence of isoproterenol at 1- to 3-Hz pacing. Early afterdepolarizations occurred at lower pacing frequency; diverse patterns of action potential were shown in all pacing frequencies. Bottom, The enlarged membrane oscillations occurring between stimulated beats. From Liu N et al. *Circulation Research* 2013;113:142–152⁷⁷.




Figure 4. Schematic diagram of a t-tubule and associated junctional SR
 Microfolds in t-tubule are depicted based on recent findings. Different arrangements of Ca²⁺ cycling proteins and sodium channels are depicted along the t-tubule. Regions highlighted by the dashed boxes are presented at higher magnification in *C* and *D*. Note that differential shading of the interstitial space within the t-tubule and the cytoplasm within the dyadic cleft indicates local differences in ionic concentrations within these spaces due to their diffusional isolation from the bulk interstitial space and cytoplasm, respectively. *B*, results from Duolink assays (PLAs) show close association of nNaV isoform Na_v1.6 with both RYR2 and NCX throughout myocytes, consistent with enrichment of nNa_vs in t-tubules. In contrast, PLA signal corresponding to association between cNa_v (Na_v1.5) and RYR2 is only observed at the periphery of the cell, consistent with cNa_v localization at the lateral membrane. Adapted from Radwa ski *et al.* 2016, doi:10.1016/j.jacbts.2016.04.004, Creative Commons

Attribution-NonCommercial-No Derivatives License (CC BY NC ND). *C*, higher magnification views of regions from *A* showing two possible scenarios of nNa_v localization within t-tubules. Left, case 1, very close association between nNa_vs and RYRs, which is consistent with PLA results. A cNa_v is depicted faded since experimental results including PLA results argue against cNa_v enrichment in t-tubules. Right, case 2, nNa_vs localized to t-tubules but not very closely associated with RYRs, which is *not* consistent with PLA results. *D*, higher magnification view of region from *A* showing cNa_v (Na_v1.5) localization at the lateral membrane. From Veeraraghavan et al, The Journal of Physiology, © 2017 The Physiological Society.³⁷ Reproduced by permission of John Wiley and Sons, Inc.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 5. JTV519(K201) suppresses cell wide Ca waves in Purkinje cells from the infarcted heart A, Graph showing the incidence of cell wide Ca²⁺ waves in Normal Zone Purkinje Cells(NZPCs) and Infarct Zone Purkinjes (IZPCs) in the absence and presence of JTV519 (K201) 1 $\mu\text{mol/L}$ (gray bar). B, Ca event rate, spatial extent, and amplitude in IZPCs in the absence and presence of JTV519 (K201) (gray bars). Total number of events used is shown in parentheses. From Hirose M et al. *Circ Arrhythm Electrophysiol* 2008;1:387-395⁸.